(858) 665-2278

Epitalon Legal Status in the US, EU, and Russia
RESEARCH USE ONLY - NOT FDA-APPROVED

Epitalon is not approved by the U.S. FDA for human use and is not lawful to administer to humans. Where it is offered for sale in the U.S., it is sold only as a 'Research Use Only' laboratory chemical, not as a medicine.

Status as of July 14, 2026

Is Epitalon approved by the FDA as a drug or dietary supplement in the United States?

The FDA recognizes two doors to the market, and the record shows Epitalon approved through neither. The drug pathway demands an investigational new drug program, clinical trials, and an approved new drug application tied to a specific indication, none of which Epitalon has completed. The supplement pathway requires a recognized dietary ingredient, a definition a laboratory-synthesized tetrapeptide does not meet, and the agency has treated many synthetic peptides as excluded from the supplement category because they were first studied as drugs.

Criteria Drug pathway Supplement pathway
Statutory gate IND program plus an approved NDA tied to an indication Built from a recognized dietary ingredient
Epitalon's fit Never completed; no approved labeling, dose, or indication Synthetic tetrapeptide fails the dietary-ingredient definition
Fallback route Not applicable NDI notification foreclosed for peptides first studied as drugs
Non-Negotiable

Epitalon has never completed a new drug application and does not meet the statutory definition of a dietary ingredient, leaving it with no lawful commercial category for human use under either FDA pathway.

Is Epitalon classified as a controlled or scheduled substance?

The federal answer is no, and the state answer is increasingly not so simple. Epitalon does not appear on any schedule of the federal Controlled Substances Act and is not reached by the federal analog statutes, which target substances with abuse and dependence profiles a bioregulator peptide does not present. What has shifted is the state layer, where a handful of legislatures have moved the peptide into their own controlled-substance regimes.

Federal level: Not scheduled under the Controlled Substances Act and not caught by the analog statutes.
Those provisions aim at stimulant, opioid, and hallucinogen-type abuse profiles Epitalon does not share.
State level: A small but growing number of states now impose their own controls.
Louisiana schedules it as Schedule I under Act 358; California restricts it under AB 2610, with similar bills pending elsewhere.
What the Rules Say

Epitalon is not federally scheduled, but Louisiana classifies it as a Schedule I controlled substance under Act 358 and California restricts it under AB 2610, so state law can make possession an offense even where federal law does not.

Is it lawful for a compounding pharmacy to prepare Epitalon for injection?

Compounding does not give Epitalon a clean legal path. A pharmacy may compound from a bulk drug substance only when that substance is the subject of an approved application, appears in a recognized pharmacopeial monograph, or sits on the FDA's section 503A bulk list, and Epitalon satisfies none of the three. The point has sharpened as the FDA moved Epitalon and related peptides into formal review of their compounding eligibility, a pending process that is not itself any form of approval.

  • 503A gate: Eligibility requires an approved application, a pharmacopeial monograph, or a place on the bulk list.
  • Epitalon's status: It meets none of the three, so compounding falls outside the statutory safe harbor.
  • Pending review: A Pharmacy Compounding Advisory Committee review is set for July 2026, with the FDA proposing not to add it.
  • Sterility bar: Injectable preparation must meet USP standards a raw research-grade peptide cannot satisfy.
Compliance Note

Epitalon is not an approved drug, carries no pharmacopeial monograph, and is not on the FDA's section 503A bulk list, so compounding it into an injectable falls outside the statutory safe harbor and remains under a Pharmacy Compounding Advisory Committee review scheduled for July 2026.

How does Epitalon's regulatory standing in Russia differ from the United States and the European Union?

The sharpest contrast is one of origin and acceptance. Epitalon traces to a St. Petersburg institute focused on bioregulation and gerontology, where peptide bioregulators have been studied and used domestically for decades and carry a formal footing that does not exist in the West. The United States and the European Union evaluate a medicine strictly through their own approval systems and give no automatic recognition to a foreign registration, so the same molecule can be a familiar domestic product in one country and an unapproved research chemical in another.

Jurisdiction Standing Basis
Russia Long domestic footing for peptide bioregulators Decades of domestic study from a St. Petersburg institute
United States Unapproved research chemical No FDA dossier of quality, safety, and efficacy submitted
European Union Unapproved medicine No EMA authorization; a foreign registration is not recognized
Head-to-Head Verdict

Drug legality is national and never inherited across borders, so Epitalon's decades-long footing in Russian bioregulator research confers no approved status with either the FDA or the EMA.

Has the European Medicines Agency authorized or evaluated Epitalon?

There is no EMA authorization for Epitalon, and the substance sits entirely outside the European approval system just as it does in the United States. In the EU, anything presented as treating or affecting the body's functions is a medicinal product that needs authorization before sale, so a peptide marketed for anti-aging effects would be an unauthorized medicine. It does not slot cleanly into the food side of EU law either, where the novel food framework gatekeeps any genuinely new ingredient behind a pre-market safety authorization.

  • Authorization: None; no centralized EMA marketing authorization exists and it is not an EMA-evaluated medicine.
  • Medicine rule: A product marketed to affect the body's functions is a medicinal product needing authorization first.
  • Food route: The novel food framework requires a pre-market safety authorization a synthetic peptide would not pass by default.
  • Enforcement: National competent authorities issue withdrawals and sales bans against unauthorized medicines.
Regulatory Reality

The European Medicines Agency has neither authorized nor evaluated Epitalon, leaving it available in Europe only through the same unregulated gray-market channels found in the United States.

Where does Epitalon stand under sports anti-doping rules such as the WADA Prohibited List?

For competitive athletes the exposure runs through a specific and often overlooked provision. Even where Epitalon is not called out by name, the World Anti-Doping Code carries an S0 category covering any substance not currently approved by any government health authority for human therapeutic use, including research chemicals still outside the approval system. An unapproved peptide available only through research channels fits that description almost exactly, so the absence of its name from the list offers no safe harbor.

  • S0 category: Covers any substance not approved by a government health authority for human therapeutic use.
  • Epitalon's fit: An unapproved research-channel peptide falls squarely within that class.
  • Scope: S0 is prohibited at all times, both in and out of competition.
  • Consequence: Strict liability means a violation brings multi-year ineligibility and disqualification regardless of intent.
Code Requirement

Even though Epitalon is not named on the WADA Prohibited List, its lack of approval by any government health authority places it under the S0 category, which is prohibited at all times, both in and out of competition.

What rules govern an individual importing or possessing Epitalon for personal use?

For an individual, the distinction that matters most is between possession and importation, and the two carry very different exposure. Because Epitalon is not a federally scheduled substance, simply holding it is generally not a federal crime, though that no longer holds in states such as Louisiana and California. Importation is a separate question entirely, layered on top of the concrete hazard of a gray-market product with no verified identity, purity, or sterility.

Possession: Generally not a federal crime because Epitalon is unscheduled, though Louisiana and California now attach state-level criminal exposure.
Importation: An unapproved new drug arriving from abroad is subject to refusal, detention, or destruction at the border, and a flagged package can simply disappear with a notice.
By country: Import regimes vary, and some jurisdictions treat unauthorized medicines far more strictly than a routine seizure.
Worth Understanding

For an individual, possessing Epitalon is generally not a federal offense while importing it exposes the shipment to refusal, detention, or destruction at the border, and a gray-market product carries no verified identity, purity, or sterility.

Educational use only. This article describes what the published scientific and clinical literature reports about Epitalon. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.

This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.

Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.

Daniel Zengel
Written by Daniel Zengel
Medical Writer
Daniel Zengel is the principal owner of MD PEP and PRP Labs and a medical writer focused on neutral, primary‑source‑driven coverage of the peptide market. He draws on more than a decade in pharmaceutical and medical device roles, with a focus on regenerative medicine and platelet‑rich plasma (PRP) systems for US‑based clinics.

Need more help?

Have a question about this peptide? Send a note and we'll point you in the right direction.

Why you can trust this page

Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.